European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...
The American Journal of Managed Care6y
Severity of Hereditary Angioedema, Prevalence, and Diagnostic Considerations
12 As with other diseases that are characterized by acute attacks, such as asthma, the burden of HAE is not only economic but also impacts the patient’s quality of life, education, relationships ...
PMLive9d
MHRA approves CSL’s Andembry to treat angioedema attacks in HAE patients
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...
Hosted on MSN9mon
‘I looked like The Elephant Man’: Life with extreme swelling disease HAE
That’s how my parents knew that I had hereditary angioedema (HAE) – a rare disease that I’d inherited from my dad. HAE is caused by a deficiency in C1 inhibitor (C1-INH) in the blood and it ...
Portugal approves daily oral therapy for hereditary angioedema
RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), a biotechnology company with impressive revenue growth of nearly 30% over the last twelve months, has announced that ...
pharmaphorum7y
Shire plans filing for HAE drug after phase 3 success
Shire noted that the study was representative of the full HAE disease spectrum. Overall, 52% of the study’s 125 patients experienced three or more attacks per month at baseline, 65% of patients ...
The Register-Herald4d
WVU Medicine successfully diagnoses West Virginia woman’s mysterious illness
At only 27 years old, Daniela Powers felt like she was dying. What began as unexplained rashes exploded into a debilitating ...
pharmaphorum11y
Shire boosts rare disease portfolio with acquisition of ViroPharma
HAE is a rare genetic disease that affects approximately 8000 patients in the US, although Shire believes only 3,500 of these patients actively manage their disease. HAE is characterised by ...
Healio29d
Lanadelumab increases attack-free rates in hereditary angioedema patients
A total of 82 patients (41.4%) began lanadelumab because of a lack of response to other HAE prophylactic therapy, 42 patients (21.2%) due to a lack of disease control before on-demand therapy and ...